Strategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy
Gene therapy using the adeno-associated virus (rAAV) to deliver mini/micro- dystrophin is the current promising strategy for Duchenne Muscular Dystrophy (DMD). However, the further transformation of this strategy still faces many “bottlenecks”. Most gene therapies are only suitable for infants with...
Main Authors: | Na Li, Yafeng Song |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/13/11/2021 |
Similar Items
-
A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation
by: Yu Zhang, et al.
Published: (2021-09-01) -
Duchenne muscular dystrophy: an historical treatment review
by: Lineu Cesar Werneck, et al. -
A rare case of dystrophinopathy: Duchenne muscular dystrophy–Becker muscular dystrophy intermediate complex
by: Rachna Gulati, et al.
Published: (2022-01-01) -
Strengthen the research of Duchenne muscular dystrophy in China
by: Cheng ZHANG
Published: (2015-06-01) -
Rehabilitation therapy of Duchenne muscular dystrophy
by: Cheng ZHANG, et al.
Published: (2012-06-01)